ISPOR Europe Conference 2019
This week, Directors Brett Gardiner and Rachel Howard attended the ISPOR Europe conference in Copenhagen, Denmark
On November 4th to 6th, Directors Brett Gardiner and Rachel Howard joined 5,500 other healthcare leaders in attending the ISPOR Europe 2019 conference in Copenhagen, Denmark. The conference opened with an announcement that four Nordic countries have pledged to spend 5% of their GDP on preventive healthcare by 2030, a significant investment in the health of these Nations. This was a timely announcement given the three-day program of events centered around the theme of ‘Digital Transformation of Healthcare’.
How we helped our client understand current and future combination pricing strategies in the Multiple Myeloma market
Our client had their product for multiple myeloma (MM) approved in several lines of therapy combined with different backbones. Their product was also being studied in some other indications with additional backbones and was anticipated to receive approval in the coming years. With several other competitive therapies available on the market, including many branded combination products, our client anticipated that payers might start considering strategies to manage combination therapies in the future. Therefore, they wanted to understand what the current and future combination pricing strategies were for oncology products, with a focus on MM and their product.
How we helped assess the asthma market landscape in emerging markets
Our client was jointly developing a fully-human monoclonal antibody (mAB) with a number of potential immunological indications. In order to prepare for launch, primary and secondary market research was required to understand more fully the asthma landscape.
What to consider when conducting pricing research
Tom Nolte, Director of Business Analytics and Boon Yap, Associate Consultant discuss how to use qualitative research and integrated modelling to optimise price and inform demand forecasts.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).